|
Market Closed -
Hong Kong S.E.
09:08:09 23/10/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.1400 HKD | 0.00% |
|
0.00% | +25.00% |
| 09-18 | Imagi International Scraps HK$167 Million Share Subscription | MT |
| 08-13 | Aceso Life Science Group Limited Reports Earnings Results for the Full Year Ended March 31, 2026 | CI |
Company Valuation: Aceso Life Science Group Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,574 | 472.4 | 1,314 | 1,174 | 369.1 | 1,054 |
| Change | - | -69.98% | 178.13% | -10.67% | -68.55% | 185.6% |
| Enterprise Value (EV) 1 | 3,660 | 2,765 | 3,634 | 3,443 | 2,458 | 1,936 |
| Change | - | -24.43% | 31.41% | -5.26% | -28.6% | -21.23% |
| P/E | -3.59x | -1.15x | -4.93x | -2.5x | -0.4x | 2.62x |
| PBR | 0.66x | 0.24x | 0.85x | 1.27x | 30.8x | 2.31x |
| PEG | - | 0.1x | 0.1x | -0x | -0x | -0x |
| Capitalization / Revenue | 16.1x | 2.78x | 6.35x | 107x | -5.2x | -17.9x |
| EV / Revenue | 37.3x | 16.3x | 17.6x | 313x | -34.6x | -32.8x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0633 | -0.0555 | -0.0361 | -0.0635 | -0.1244 | 0.0454 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 98 | 170 | 207 | 11 | -71 | -59 |
| EBITDA | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - |
| Net income 1 | -376 | -370 | -264 | -462 | -895 | 338 |
| Net Debt 1 | 2,086 | 2,293 | 2,320 | 2,269 | 2,089 | 882 |
| Reference price 2 | 0.2270 | 0.0640 | 0.1780 | 0.1590 | 0.0500 | 0.1190 |
| Nbr of stocks (in thousands) | 6,931,887 | 7,381,777 | 7,381,777 | 7,381,777 | 7,381,777 | 8,858,127 |
| Announcement Date | 22/07/21 | 28/07/22 | 26/07/23 | 26/07/24 | 30/07/25 | 20/08/26 |
1HKD in Million2HKD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 158M | |
| 25.67x | 4.41x | 19.7x | 0.9% | 316B | |
| 35.67x | 5.54x | 30.16x | 1.02% | 174B | |
| 14.94x | 1.12x | 7.27x | 5.14% | 63.04B | |
| 17.97x | 1.66x | 13.47x | 3.03% | 56.3B | |
| 29.17x | 4.12x | 17.18x | 0.46% | 45.7B | |
| 15.01x | 1.54x | 8.78x | 2.89% | 38.14B | |
| 10.94x | 1.04x | 10.37x | 4.78% | 34.08B | |
| 30.42x | 4.43x | 17.67x | 1.64% | 29.07B | |
| 12.36x | 0.4x | 4.17x | 3.98% | 26.08B | |
| Average | 21.35x | 2.69x | 14.31x | 2.65% | 78.26B | |
| Weighted average by Cap. | 25.26x | 3.76x | 18.90x | 1.79% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 474 Stock
- Valuation Aceso Life Science Group Limited
Select your edition
All financial news and data tailored to specific country editions
